Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 11/20 | 1.00 |
| ▸ | MMP8 | P22894 | 11/20 | 1.00 |
| ▸ | MMP1 | P03956 | 11/20 | 1.00 |
| ▸ | MMP9 | P14780 | 9/20 | 1.00 |
| ▸ | MMP7 | P09237 | 5/20 | 1.00 |
| ▸ | MMP3 | P08254 | 5/20 | 1.00 |
| ▸ | FCER2 | P06734 | 4/20 | 1.00 |
| ▸ | MMP13 | P45452 | 3/20 | 0.82 |
| ▸ | MMP12 | P39900 | 2/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5099222 | 0.89 | MMP2 (0.80) | MMP2MMP8MMP1MMP9MMP7 | |
| SCHEMBL4634581 | 0.88 | MMP2 (1.00) | MMP2MMP8MMP1MMP9MMP7 | |
| SCHEMBL4634587 | 0.88 | MMP2 (1.00) | MMP2MMP8MMP1MMP9MMP7 | |
| SCHEMBL4634577 | 0.88 | MMP2 (1.00) | MMP2MMP8MMP1MMP9MMP7 | |
| SCHEMBL8271136 | 0.88 | MMP2 (0.79) | MMP2MMP8MMP1MMP9MMP7 | |
| SCHEMBL29838142 | 0.88 | MMP2 (1.00) | MMP2MMP8MMP1MMP9MMP7 | |
| SCHEMBL5556836 | 0.87 | MMP2 (1.00) | MMP2MMP8MMP1MMP9MMP7 | |
| SCHEMBL5552919 | 0.87 | MMP2 (1.00) | MMP2MMP8MMP1MMP9MMP7 | |
| SCHEMBL5552911 | 0.87 | MMP2 (1.00) | MMP2MMP8MMP1MMP9MMP7 | |
| SCHEMBL9284838 | 0.86 | MMP1 (1.00) | MMP2MMP8MMP1MMP9MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9745567-B2 | Compositions and methods for treating multiple sclerosis | REVALESIO CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| US-9523090-B2 | Compositions and methods for treating inflammation | REVALESIO CORPORATION (US) | 2016-12-20 | — | — | US | disclosed |
| US-20120114702-A1 | COMPOSITIONS AND METHODS FOR TREATING ASTHMA AND OTHER LUNG DISORDERS | REVALESIO CORPORATION | 2012-05-10 | — | — | US | disclosed |
| US-20100098659-A1 | COMPOSITIONS AND METHODS FOR TREATING MATRIX METALLOPROTEINASE 9 (MMP9)-MEDIATED CONDITIONS | REVALESIO CORPORATION (US) | 2010-04-22 | — | — | US | disclosed |
| US-20100098659-A1 | COMPOSITIONS AND METHODS FOR TREATING MATRIX METALLOPROTEINASE 9 (MMP9)-MEDIATED CONDITIONS | REVALESIO CORPORATION (US) | 2010-04-22 | — | — | US | disclosed |
| US-20100028443-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATION | REVALESIO CORPORATION (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100028441-A1 | COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS | REVALESIO CORPORATION (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100015235-A1 | COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS | REVALESIO CORPORATION (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100015235-A1 | COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS | REVALESIO CORPORATION (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100008997-A1 | COMPOSITIONS AND METHODS FOR TREATING ASTHMA AND OTHER LUNG DISORDERS | REVALESIO CORPORATION (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100004189-A1 | COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS | REVALESIO CORPORATION (US) | 2010-01-07 | — | — | US | disclosed |
| EP-1796602-A2 | MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE | Angiotech Pharmaceuticals (US), Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006083260-A2 | COMPOSITIONS AND SYSTEMS FOR FORMING CROSSLINKED BIOMATERIALS AND ASSOCIATED METHODS OF PREPARATION AND USE | ANGIOTECH BIOMATERIALS CORPORATION (US) | 2006-08-10 | — | — | WO | disclosed |
| WO-2006078282-A2 | COMPOSITIONS AND SYSTEMS FOR FORMING CROSSLINKED BIOMATERIALS AND ASSOCIATED METHODS OF PREPARATION AND USE | ANGIOTECH BIOMATERIALS CORPORATION (US) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006034128-A2 | MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE | ANGIOTECH BIOMATERIALS CORPORATION (US) | 2006-03-30 | — | — | WO | disclosed |
| EP-1060161-B1 | MATRIX METALLOPROTEINASE INHIBITORS | LEO PHARMA AS WITH SECONDARY N (DK) | 2003-06-11 | — | — | EP | disclosed |
| US-6277876-B1 | Matrix metalloproteinase inhibitors | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2001-08-21 | — | — | US | disclosed |
| US-5919940-A | TERT-LEUCINE-THIAZOL-2-YLAMIDE | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-07-06 | — | — | US | disclosed |
| US-5859253-A | L-TERT-LEUCINE-2-PYRIDYLAMIDE | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-01-12 | — | — | US | disclosed |
| US-5747514-A | Metalloproteinase inhibitors | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1998-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100015235-A1 | COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS | GJA1, GJB2, GPR180 | MMP2 3607/4885MMP8 1204/4885MMP1 1996/4885 |
| US-20120114702-A1 | COMPOSITIONS AND METHODS FOR TREATING ASTHMA AND OTHER LUNG DISORDERS | CHRM3, CHRNG, GRK3 | MMP2 2528/4885MMP8 793/4885MMP1 1698/4885 |
| US-20100028443-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATION | EPCAM, GPR180, GJA1 | MMP2 2975/4885MMP8 256/4885MMP1 1268/4885 |
| US-20100004189-A1 | COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS | CFTR, GJB2, KRAS | MMP2 2983/4885MMP8 1039/4885MMP1 748/4885 |
| US-20100098659-A1 | COMPOSITIONS AND METHODS FOR TREATING MATRIX METALLOPROTEINASE 9 (MMP9)-MEDIATED CONDITIONS | MMP9, MMP14, MMP10 | MMP2 11/4885MMP8 19/4885MMP1 12/4885 |
| US-20100028441-A1 | COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS | GJA1, GPR180, AQP4 | MMP2 3526/4885MMP8 1463/4885MMP1 1096/4885 |
| US-20100008997-A1 | COMPOSITIONS AND METHODS FOR TREATING ASTHMA AND OTHER LUNG DISORDERS | RGS17, RGS16, CHRM3 | MMP2 2273/4885MMP8 626/4885MMP1 1856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.